Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
- Registration Number
- NCT03039114
- Lead Sponsor
- Incyte Corporation
- Brief Summary
The purpose of this study is to evaluate the safety and efficacy of parsaclisib when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26
- Histologically confirmed FL.
- Documented CD20+ FL.
- Relapsed or refractory to any prior rituximab-containing regimen.
- Previously treated with a maximum of 4 cancer-directed treatment regimens.
- At least 1 measurable lesion > 1.5 cm in at least 1 dimension by computed tomography or magnetic resonance imaging.
- Must be willing to undergo an incisional or excisional lymph node biopsy of accessible adenopathy or provide the most recent, available archived tumor biopsy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Clinical evidence of transformation to a more aggressive subtype of lymphoma or Grade 3B FL.
-
History of central nervous system lymphoma (either primary or metastatic).
-
Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug administration.
-
Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug.
-
Prior treatment with a selective PI3Kδ inhibitor or a pan PI3K inhibitor.
-
Prior treatment with bendamustine (within 12 months of the start of study treatment). Subjects with prior bendamustine treatment (> 12 months before the start of study treatment) are eligible if they meet the following criteria:
- Did not discontinue because of tolerability concerns.
- Achieved either partial or CR to the bendamustine regimen of at least 12 months in duration before relapse/progression.
- Experienced progression following a regimen containing an alkylating agent.
-
Received prior obinutuzumab.
-
Received rituximab within 4 weeks of study start.
-
Prior treatment-related toxicities that have not resolved to ≤ Grade 1 before the date of study drug administration except for stable chronic toxicities (≤ Grade 2) not expected to resolve (eg, stable Grade 2 peripheral neurotoxicity).
-
Received any prior monoclonal antibody (except an anti-CD20 antibody) within 90 days before the date of study start.
-
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (eg, subjects in whom re-administration with rituximab would be contraindicated for safety reasons).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Parsaclisib + Hexal and Gazyvaro Hexal - Parsaclisib + Hexal and Gazyvaro Gazyvaro - Parsaclisib + Hexal and Gazyvaro Parsaclisib -
- Primary Outcome Measures
Name Time Method Safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory FL, assessed by number of subjects with adverse events (AEs) Screening through 30-35 days after end of treatment, up to approximately 34 months per subject
- Secondary Outcome Measures
Name Time Method Objective response rate based on Lugano classification criteria Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject Defined as percentage of subjects with a complete response (CR) and partial response (PR), as determined by investigator assessment of response
Complete response rate based on Lugano classification criteria Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject Defined as percentage of subjects who achieve a best overall response of CR
Progression-free survival Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject Defined as time from the date of the first dose of study drug until the earliest date of disease progression (determined by radiographic disease assessment/Lugano classification criteria) or death due to any cause.
Duration of response Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject Defined as time from first documented evidence of CR or PR until earliest date of disease progression or death due to any cause.
Overall survival From the date of the first dose of study drug until death due to any cause, assessed up to approximately 34 months per subject Defined as the time from the date of the first dose of study drug until death due to any cause.
Trial Locations
- Locations (21)
UO Ematologia ASST Spedali Civili
🇮🇹Brescia, Italy
Clinical Research Alliance
🇺🇸Lake Success, New York, United States
University of Kansas Cancer Center
🇺🇸Fairway, Kansas, United States
Rigshospitalet
🇩🇰Copenhagen, Denmark
Banner Health
🇺🇸Gilbert, Arizona, United States
Center for Cancer and Blood Disorders (CCBD) - Bethesda
🇺🇸Bethesda, Maryland, United States
Froedtert & Medical College of Wisconsin & Affiliated Hospitals
🇺🇸Milwaukee, Wisconsin, United States
University of California, San Diego
🇺🇸La Jolla, California, United States
FN Ostrava / Ostrava
🇨🇿Ostrava, Czechia
The Finsen Centre, National Hospital
🇩🇰Copenhagen, Denmark
Aarhus University Hospital
🇩🇰Aarhus, Denmark
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Centro di Riferimento Oncologico
🇮🇹Aviano, Italy
Azienda Ospedaliero Universitaria Di Bologna
🇮🇹Bologna, Italy
Policlinico S. Orsola-Ematologia LA Seragnoli
🇮🇹Bologna, Italy
A.O. Spedali Civili
🇮🇹Brescia, Italy
Hospital Universitario Virgen del Rocío
🇪🇸Sevilla, Spain
Hospital Universitario Gregorio Marañón
🇪🇸Madrid, Spain
Hospital Germans Trias Pujol
🇪🇸Barcelona, Spain
Hospital Universitario Fundación Jiménez Díaz
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain